Statistics

Total Visits

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial70

Select a period of time:

Number of views in the range

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial20

Views

Views
December 20250
January 20262
February 20260
March 20267
April 20261
May 20263
June 20267
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
Netherlands3
Spain3
Angola1
Argentina1
Colombia1
United Kingdom1
Iran1
Italy1
Trinidad and Tobago1
 

Top cities views

Views
Groningen3
San Jose2
Madrid2
Bogotá1
Caracas1
Córdoba1
Jersey City1
Milan1
Port of Spain1
Sarria1